301075.SHE Tibet Duo Rui Pharmaceutical Co.Ltd.
- Market cap
- CNY 3.64B
- P/E
- -
- P/B
- 5.55x
- ROE
- 1.7%
- Dividend yield
- 0.24%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301075.SHE undervalued?
Graham numberThe Graham number of Tibet Duo Rui Pharmaceutical Co.Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tibet Duo Rui Pharmaceutical Co.Ltd. fundamental analysis
No fundamental analysis for Tibet Duo Rui Pharmaceutical Co.Ltd. yet.
Tibet Duo Rui Pharmaceutical Co.Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tibet Duo Rui Pharmaceutical Co.Ltd.
Tibet Duo Rui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical formulations, chemical intermediates, and peptide APIs in China. It offers fluid therapy, anesthesiology medication, analgesic medication, and first-aid medication products, as well as multiple electrolytes injection; sodium acetate ringer's injection. Tibet Duo Rui Pharmaceutical Co., Ltd. was founded in 2005 and is headquartered in Tibet, China.
Full company profileTibet Duo Rui Pharmaceutical Co.Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tibet Duo Rui Pharmaceutical Co.Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 449M | 490M | 530M | 401M | 334M | 241M | 154M | 199M |
| Gross Profit | 426M | 446M | 469M | 309M | 229M | 102M | 12.6M | 26.1M |
| Operating Income | 83.4M | 105M | 75.1M | 16.6M | 11.9M | -70.6M | -94.5M | -51.3M |
| EBITDA | 125M | 144M | 89.3M | 38.2M | 44.3M | -48.4M | -61.1M | 17.3M |
| Net Income | 71.7M | 92.0M | 68.5M | 20.5M | 18.9M | -62.7M | -102M | 11.4M |
| EPS | 1.76 | 1.53 | 0.86 | 0.26 | 0.24 | -0.78 | -1.28 | 0.14 |
| Balance Sheet | ||||||||
| Total Assets | 294M | 373M | 851M | 899M | 1.07B | 1.53B | 1.28B | 1.46B |
| Total Liabilities | 144M | 132M | 62.8M | 145M | 251M | 782M | 660M | 768M |
| Shareholders' Equity | 150M | 242M | 793M | 752M | 772M | 677M | 575M | 657M |
| Cash & Short-term Investments | 95.6M | 104M | 611M | 426M | 405M | 262M | 85.3M | 153M |
| Cash Flow | ||||||||
| Operating Cash Flow | 35.3M | 63.6M | 48.1M | 1.13M | 12.4M | -67.2M | -45.8M | - |
| Capital Expenditure | 12.7M | 50.8M | 5.35M | 32.7M | 23.7M | 40.9M | 102M | 114M |
| Free Cash Flow | 22.6M | 12.8M | 42.8M | -31.6M | -11.3M | -108M | -148M | -199M |
| Ratios | ||||||||
| ROE | 47.7% | 38.0% | 8.6% | 2.7% | 2.4% | -9.3% | -17.8% | 1.7% |
| ROA | 24.4% | 24.7% | 8.0% | 2.3% | 1.8% | -4.1% | -8.0% | 0.8% |
| Net Profit Margin | 16.0% | 18.8% | 12.9% | 5.1% | 5.6% | -26.0% | -66.3% | 5.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Tibet Duo Rui Pharmaceutical Co.Ltd. dividends
- Dividend yield
- 0.24%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 31, 2024
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 8.79M | 0.11 | - |
| 2024 | CNY 17.1M | 0.21 | - |
| 2023 | CNY 3.25M | 0.04 | 17.3% |
| 2022 | CNY 50.8M | 0.64 | 248.0% |
| 2021 | CNY 1.15M | 0.01 | 1.7% |
| 2020 | CNY 2.07M | 0.03 | 2.3% |
| 2019 | CNY 2.14M | 0.05 | 3.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Tibet Duo Rui Pharmaceutical Co.Ltd.
- Insiders 67.49%
- Institutions 1.60%
- Public & others 30.91%
- Shares outstanding 80.0M
- Free float 70.0M
Tibet Duo Rui Pharmaceutical Co.Ltd. company profile
- Company name
- Tibet Duo Rui Pharmaceutical Co.Ltd.
- Ticker
- 301075.SHE
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 461
- Fiscal year end
- December
- Address
- Building 1, Tibet, China
- Phone
- 86 89 5489 2099
- Website
- duoruiyy.com
About Tibet Duo Rui Pharmaceutical Co.Ltd.
Tibet Duo Rui Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical formulations, chemical intermediates, and peptide APIs in China. It offers fluid therapy, anesthesiology medication, analgesic medication, and first-aid medication products, as well as multiple electrolytes injection; sodium acetate ringer's injection. Tibet Duo Rui Pharmaceutical Co., Ltd. was founded in 2005 and is headquartered in Tibet, China.
Tibet Duo Rui Pharmaceutical Co.Ltd. management
1- Mr. Bo AoDeputy GM & Board Secretary · born 1986